Gene-Therapy against Epilepsy - CombiGene




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Gene-Therapy against Epilepsy - CombiGene
Released on: November 09, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Serial biotech entrepreneur Bengt Westrin talks with Nigel Borshell of PharmaVentures about his latest enterprise, a Swedish preclinical CNS company called CombiGene that has been formed further to an academic collaboration between Lund University and University of Copenhagen.
  • Summary
  • Transcript
  • Participants
  • Company
Serial biotech entrepreneur Bengt Westrin talks with Nigel Borshell of PharmaVentures about his latest enterprise, a Swedish preclinical CNS company called CombiGene that has been formed further to an academic collaboration between Lund University and University of Copenhagen. CombiGene is developing a gene therapy for the treatment of drug resistant epilepsy, which represents a very large unmet medical need.
Serial biotech entrepreneur Bengt Westrin talks with Nigel Borshell of PharmaVentures about his latest enterprise, a Swedish preclinical CNS company called CombiGene that has been formed further to an academic collaboration between Lund University and University of Copenhagen. CombiGene is developing a gene therapy for the treatment of drug resistant epilepsy, which represents a very large unmet medical need.
Bengt Westrin, born 1958, is CEO of CombiGene since March 2015. Bengt has a PhD from Lund University and is an Associate Professor at Lund University since 1999. Bengt has extensive experience from both startup companies and large pharmaceutical companies and extensive knowledge in everything from product development and regulatory issues to project management and business development. Bengt has been CEO of Lipopeptide AB and CEO and Chairman of Idogen AB. Bengt is currently Project Manager (part time) on AcuCort AB.
CombiGene is by combining advances in neuroscience and modern genetic engineering developed a treatment method in preclinical studies been shown to prevent seizures. The company focuses in the current situation to further develop this treatment so it can get epilepsy patients benefit. The Board believes, however CombiGenes' treatment potential to be developed so that it can be used also for other brain-related diseases.